Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

Wang, Shujing; Liu, Huiqin; Zhang, Xinyi; Feng, Qian

doi:10.1007/s13238-015-0164-2

Cited by 130 publications

(109 citation statements)

References 249 publications

(306 reference statements)

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…Synthesized using colloidal saponin (often QuilA extracted from the tree Quillaja saponaria ), cholesterol and other phospholipids (generally phosphatidylethanolamine or phosphatidylcholine), these nano-sized vectors (~40 nm) with self-adjuvant abilities are organized in open-caged structures [15,21,162,163]. These vehicles have been used to entrap bacterial and viral envelope proteins to prompt vaccines against such pathogens.…”

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

319

275

View full text Add to dashboard Cite

While vaccination remains the most cost effective strategy for disease prevention, communicable diseases persist as the second leading cause of death worldwide. There is a need to design safe, novel vaccine delivery methods to protect against unaddressed and emerging diseases. Development of vaccines administered orally is preferable to traditional injection-based formulations for numerous reasons including improved safety and compliance, and easier manufacturing and administration. Additionally, the oral route enables stimulation of humoral and cellular immune responses at both systemic and mucosal sites to establish broader and long-lasting protection. However, oral delivery is challenging, requiring formulations to overcome the harsh gastrointestinal (GI) environment and avoid tolerance induction to achieve effective protection. Here we address the rationale for oral vaccines, including key biological and physicochemical considerations for next-generation oral vaccine design.

show abstract

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

“…T cell-mediated), and only weak protection generated at the mucosal surfaces [10,11]. In contrast, vaccination at mucosal surfaces successfully induces mucosal antibodies (IgA) and cell-mediated immune responses, while still producing a systemic antibody response (IgG) [12–15]. …”

Section: Introductionmentioning

confidence: 99%

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

319

275

View full text Add to dashboard Cite

show abstract

“…Another promising mucosal delivery system that has been recently reviewed by Wang et al is the polyacryl starch microparticles [122]. It not only protects the protein antigens from degradation, but also helps to facilitate the release of the encapsulated antigen and to boost the immune response upon oral and intranasal administration in mice [123].…”

Section: Mucosal Vaccine Delivery Systemsmentioning

confidence: 99%

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

127

115

View full text Add to dashboard Cite

Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and concludes with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.

show abstract

“…At present, parenteral injections are generally used for administering influenza vaccinations. However, intranasal vaccination may be a more attractive, non‐invasive alternative to needle‐based injections . It is safer and can be administered by personnel without medical training.…”

Section: Introductionmentioning

confidence: 99%

Intranasal Nanovaccine Confers Homo‐ and Hetero‐Subtypic Influenza Protection

Zhang

Sun

et al. 2018

Small

View full text Add to dashboard Cite

Cross-protective and non-invasively administered vaccines are attractive and highly desired for the control of influenza. Self-assembling nanotechnology provides an opportunity for the development of vaccines with superior performance. In this study, an intranasal nanovaccine is developed targeting the conserved ectodomain of influenza matrix protein 2(M2e). 3-sequential repeats of M2e (3M2e) is presented on the self-assembling recombinant human heavy chain ferritin (rHF) cage to form the 3M2e-rHF nanoparticle. Intranasal vaccination with 3M2e-rHF nanoparticles in the absence of an adjuvant induces robust immune responses, including high titers of sera M2e-specific IgG antibodies, T-cell immune responses, and mucosal secretory-IgA antibodies in mice. The 3M2e-rHF nanoparticles also confer complete protection against a lethal infection of homo-subtypic H1N1 and hetero-subtypic H9N2 virus. An analysis of the mechanism of protection underlying the intranasal immunization with the 3M2e-rHF nanoparticle indicates that M2e-specific mucosal secretory-IgA and T-cell immune responses may play critical roles in the prevention of infection. The results suggest that the 3M2e-rHF nanoparticle is a promising, needle-free, intranasally administered, cross-protective influenza vaccine. The use of self-assembling nanovaccines could be an ideal strategy for developing vaccines with characteristics such as high immunogenicity, cross-protection, and convenient administration, as well as being economical and suitable for large-scale production.

show abstract

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

Cited by 130 publications

References 249 publications

Current state and challenges in developing oral vaccines

Current state and challenges in developing oral vaccines

Mucosal vaccine delivery: Current state and a pediatric perspective

Intranasal Nanovaccine Confers Homo‐ and Hetero‐Subtypic Influenza Protection

Contact Info

Product

Resources

About